STOCK TITAN

Medirom hearing request stays Nasdaq suspension for 15 days

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Medirom Healthcare Technologies Inc. (MRM) received a Nasdaq delisting notice after it missed the extended deadline to file its Form 20-F for the year ended December 31, 2025. The notice said ADS trading would be subject to suspension and delisting at the opening of business on November 24, 2026, unless the company appealed. MRM filed the annual report and requested a hearing on November 18, 2026.

The hearing request automatically stays any suspension for 15 days, and MRM requested an extended stay pending completion of the hearing process. A separate minimum bid price deficiency remains; Nasdaq gave the company until April 5, 2027 to regain compliance, and filing the annual report does not resolve it. Nasdaq and the hearing panel have not determined whether MRM will regain or maintain compliance or remain listed.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.ADS trading faced possible suspension and delisting on November 24, 2026 absent an appeal; MRM subsequently requested a hearing.
  • Moderate pointA separate minimum bid price deficiency has an April 5, 2027 compliance deadline, and the annual report does not resolve it.
Automatic suspension stay 15 days A hearing request automatically stays suspension of ADS trading for 15 days from the request date.
Notice's suspension and delisting date November 24, 2026 Nasdaq notice stated ADS trading would be subject to suspension and delisting at the opening of business unless MRM requested an appeal.
Minimum bid price compliance deadline April 5, 2027 Nasdaq deadline for MRM to regain compliance with the separate minimum bid price requirement.
American Depositary Shares regulatory
"trading of the Company’s American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Nasdaq Hearings Panel regulatory
"a hearing before a Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
Listing Rule 5250(c)(1) regulatory
"not regained compliance with Nasdaq Listing Rule 5250(c)(1)"
A Nasdaq listing standard that requires companies traded on the exchange to file their regular financial reports with the U.S. Securities and Exchange Commission on time, such as annual and quarterly reports, and to notify Nasdaq if filings are late. It matters to investors because these filings provide the routine, reliable information needed to judge a company’s health; missing them can trigger warnings, trading suspension, or removal from the exchange, which can sharply affect liquidity and share value — like a business losing its operating license for failing inspections.
periodic reporting deficiency regulatory
"resolves the Company’s periodic reporting deficiency"
minimum bid price requirement regulatory
"not in compliance with the minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
continued listing requirements regulatory
"all applicable Nasdaq continued listing requirements"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Nasdaq issue a delisting notice to MRM?

Nasdaq cited the missed deadline for MRM’s 2025 Form 20-F after the company did not file within an extension period.

When could MRM ADS trading be suspended and delisted?

At the opening of business on November 24, 2026, absent an appeal, under Nasdaq’s notice; MRM submitted a hearing request on November 18, 2026.

How long does MRM’s Nasdaq hearing request stay an ADS suspension?

The request automatically stays any suspension for 15 days from November 18, 2026; MRM also requested an extended stay pending completion of the hearing process.

What separate Nasdaq listing issue does MRM still face?

MRM also has a minimum bid price deficiency with an April 5, 2027 deadline; filing the annual report does not resolve that separate issue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2026

Commission File Number 001-39809

MEDIROM HEALTHCARE TECHNOLOGIES INC.

(Translation of registrant’s name into English)

2-3-1 Daiba, Minato-ku

Tokyo 135-0091, Japan

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨ Form 40-F

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request

 

On November 13, 2026, MEDIROM Healthcare Technologies Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) because the Company had not filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) within the extension period previously granted by Nasdaq and therefore had not regained compliance with Nasdaq Listing Rule 5250(c)(1).

 

As previously disclosed, Nasdaq notified the Company on May 26, 2026 that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed the Annual Report. Nasdaq subsequently granted the Company an extension to regain compliance. The Company did not file the Annual Report within that extension period. The Notice stated that unless the Company requests an appeal of the delisting determination, trading of the Company’s American Depositary Shares will be subject to suspension and delisting from Nasdaq at the opening of business on November 24, 2026.

 

On November 18, 2026, the Company timely submitted a request for a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the determination. Under the applicable Nasdaq rules, the hearing request automatically stays any suspension of trading in the Company’s American Depositary Shares (“ADSs”) for 15 days from the date of the request. The Notice also stated that when the Company requests a hearing, it may also request a stay of the suspension pending the hearing. The Company has requested an extended stay of any trading suspension pending completion of the hearing process.

 

The Company filed the Annual Report with the U.S. Securities and Exchange Commission on November 18, 2026. The Company has presented the filing of the Annual Report to Nasdaq in support of its appeal and request for continued listing. There can be no assurance that Nasdaq will determine that the filing resolves the Company’s periodic reporting deficiency or results in the cancelation of a hearing, that the Panel will grant any further stay of suspension or the Company’s request for continued listing, or that the Company will regain or maintain compliance with all applicable Nasdaq continued listing requirements.

 

The Notice relates to the Company’s periodic reporting deficiency. Separately, as previously disclosed, on October 6, 2026, the Company received a notice that it was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq provided the Company until April 5, 2027 to regain compliance with that requirement. Filing the Annual Report does not resolve this separate minimum bid price deficiency.

 

Issuance of Press Release

 

On November 18, 2026, the Company issued a press release announcing its receipt of the Determination from Nasdaq, the filing of the Annual Report and the submission of a hearing request. A copy of this press release is attached to this current report on Form 6-K as Exhibit 99.1.

 

The information furnished in this report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This report includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “hope,” “predict,” “potential,” “continue,” and similar expressions are intended


to identify such forward-looking statements. These forward-looking statements include the Company’s expectations with respect to future performance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include but are not limited to Nasdaq’s response in light of the filing of the Annual Report, the outcome of any hearing process, the Panel’s exercise of discretion, the Company’s ability to satisfy applicable listing requirements, and the other risks set forth under “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the SEC on November 18, 2026 and in the Company’s other filings with the SEC. There can be no assurance that the Company will be able to regain compliance with the Nasdaq requirements for continued listing within the extended compliance period. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

EXHIBIT INDEX

 

 

 

 

Exhibit No.

Description

99.1

 

Press release of the Company

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDIROM HEALTHCARE TECHNOLOGIES INC.

Date: November 18, 2026

By:

/s/ Fumitoshi Fujiwara

Name: Fumitoshi Fujiwara

Title: Chief Financial Officer

 

 


Exhibit 99.1

 

 

FOR IMMEDIATE RELEASE

MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request

TOKYO, Japan, November 18, 2026 — MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that on November 13, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) because the Company had not filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) within the extension period previously granted by Nasdaq and therefore had not regained compliance with Nasdaq Listing Rule 5250(c)(1).

As previously disclosed, Nasdaq notified the Company on May 26, 2026, that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed the Annual Report. Nasdaq subsequently granted the Company an extension to regain compliance. The Company did not file the Annual Report within that extension period. The Notice stated that unless the Company requests an appeal of the delisting determination, trading of the Company’s American Depositary Shares will be subject to suspension and delisting from Nasdaq at the opening of business on November 24, 2026.

On November 18, 2026, the Company timely submitted a request for a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the determination. Under the applicable Nasdaq rules, the hearing request automatically stays any suspension of trading in the Company’s American Depositary Shares (“ADSs”) for 15 days from the date of the request. The Notice also stated that when the Company requests a hearing, it may also request a stay of the suspension pending the hearing. The Company has requested an extended stay of any trading suspension pending completion of the hearing process.

The Company filed the Annual Report with the U.S. Securities and Exchange Commission on November 18, 2026. The Company has presented the filing of the Annual Report to Nasdaq in support of its appeal and request for continued listing. There can be no assurance that Nasdaq will determine that the filing resolves the Company’s periodic reporting deficiency or results in the cancelation of a hearing, that the Panel will grant any further stay of suspension or the Company’s request for continued listing, or that the Company will regain or maintain compliance with all applicable Nasdaq continued listing requirements.

The Notice relates to the Company’s periodic reporting deficiency. Separately, as previously disclosed, on October 6, 2026, the Company received a notice that it was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq provided the Company until April 5, 2027, to regain compliance with that requirement. Filing the Annual Report does not resolve this separate minimum bid price deficiency.

 

 


Exhibit 99.1

◼Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable U.S. securities laws, including statements regarding the Company’s appeal of the determination, any further stay of trading suspension, continued listing of the Company’s ADSs, and the Company’s ability to regain or maintain compliance with Nasdaq’s continued listing requirements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including Nasdaq’s response in light of the filing of the Annual Report, the outcome of any hearing process, the Panel’s exercise of discretion, the Company’s ability to satisfy applicable listing requirements, and the other risks described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. Except as required by law, the Company undertakes no obligation to update these statements.

◼About MEDIROM Group

img49794301_0.gif

MEDIROM Group operates approximately 281 wellness salons under the “Re.Ra.Ku®” brand nationwide. Since 2015, we have expanded into HealthTech, offering on-demand training apps like Lav® for specific health guidance and lifestyle improvement programs. In 2020, we started manufacturing the 24/7 recharge-free smart tracker “MOTHER Bracelet®,” which is now used in REMONY, our remote monitoring system for various industries including caregiving, transportation, construction, and manufacturing.

 

About MEDIROM Healthcare Technologies Inc.

NASDAQ Symbol: MRM

Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan

Website: https://medirom.co.jp/en

Contact: ir@medirom.co.jp

 

 


Filing Exhibits & Attachments

1 document

Keep reading